Company: BDRX
Filing Date: 2025-01-28
Form Type: 424B3
Source: 0001214659-25-001409
Chunk: 141

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-01-28
Form: 424B3
Chunk 141
---
 acquisitions and/or mergers, potentially available to the Company.
Any alternatives considered are contingent upon the agreement of counterparties and accordingly, there can be no assurance that any alternative
courses of action to finance the Company would be successful. This requirement for additional financing in the short term represents a
material uncertainty that may cast significant doubt upon our ability to continue as a going concern. Should it become evident in the
future that there are no realistic financing options available to the Company which are actionable before its cash resources run out then
the Company will no longer be a going concern. In such circumstances, we would no longer be able to prepare financial statements under
paragraph 25 of IAS 1. Instead, the financial statements would be prepared on a liquidation basis and assets would be stated at net realizable
value and all liabilities would be accelerated to current liabilities. As a result of the foregoing, our independent registered public
accounting firm included an explanatory paragraph in their report on our financial statements as of and for the year ended December 31,
2023 with respect to this uncertainty.

The following are considered
to be critical accounting estimates:

Impairment of Goodwill and Intangible Assets Not Yet Ready for Use

Intangible
assets not yet ready for use are tested for impairment at the cash generating unit level on an annual basis at the year end and between
annual tests if an event occurs or circumstances change that would more likely than not reduce the fair value of a cash generating unit
below its carrying value. These events or circumstances could include a significant change in the business climate, legal factors, operating
performance indicators, competition, or sale or disposition of a significant portion of a reporting unit.

The
fair value of each cash generating unit or asset is estimated using the income approach, on a discounted cash flow methodology. This analysis
requires significant judgments, including estimation of future cash flows, which is dependent on internal forecasts, including for revenues
and development costs, estimation of the long-term rate of growth for the business, estimation of the useful life over which cash flows
will occur and determination of our weighted-average cost of capital.

The
carrying value of our goodwill was £0 as of June 30, 2024 and £0 as of June 30, 2022, and intangible assets not yet ready
for use was £6.01 as of June 30, 2024 (2023: £0). The carrying value of our goodwill was £0 as of December 31, 202